The 50,000-square-foot site includes fermentation and purification equipment for the production of AA4500, laboratories for in-process and final product release testing, as well as development labs that could be useful in activities related to AA4500's life cycle management and other potential product candidates

Proceeds are expected to fund preclinical and clinical development activities, as well as the construction of a 50,000-square-foot manufacturing facility in Lansing, Mich., to be used for BioThrax

IPO proceeds are expected to fund preclinical and clinical development, as well as the construction of a 50,000-square-foot manufacturing facility in Lansing, Mich., to be used for BioThrax, and the build-out of manufacturing facilities in Frederick, Md

The company will make ABthrax in its manufacturing facilities in Rockville, Md., a 130,000-square-foot site where assays and a scalable purification process already are in place

The company will produce ABthrax in its manufacturing facilities in Rockville, a 130,000-square-foot site at which it has developed required assays and a scalable purification process

The 106,000 square foot property will be used for Northfield's first planned commercial facility for the manufacture of PolyHeme, a human hemoglobin-based oxygen carrier

Nearly 2,000 exhibitors fill about 179,000 square feet of exhibit space, and more than 255 academic posters are expected...It's a great reason to highlight food and agriculture," Greenwood said, with the high spot being the display of a 1,000-square-foot field of genetically engineered corn in the convention center

The buyout of Abgenix not only gives Amgen full rights to panitumumab, but brings aboard a 100,000-square-foot manufacturing plant and XenoMouse, the fully human monoclonal antibody technology, while eliminating a tiered royalty Amgen would have paid to Abgenix on future sales of denosumab (formerly AMG 162), which was created with XenoMouse

The research group temporarily is being housed in a building on Florida Atlantic University’s campus in Jupiter, with a 350,000-square-foot permanent facility projected for completion around mid-2008

The company also has prepared for the commercial launch of FavId by signing an amended lease agreement to expand to 80,000 square feet its existing facility for commercial-scale manufacturing

A.P. Pharma Inc., of Redwood City, Calif., submitted a protocol to the FDA for a single pivotal Phase III trial with APF530. The proposed trial will compare the safety and efficacy of APF530 with palonosetron to treat acute and delayed chemotherapy-induced nausea and vomiting in patients receiving either moderately or highly emetogenic chemotherapy. The company hopes to begin enrollment of 1,200 patients in April. Accentia Biopharmaceuticals Inc., of Tampa, Fla., said its subsidiary, Biovest

Since its inception, CeeTox has grown from four to 13 employees, and has doubled its office and lab space to nearly 4,000 square feet.

Amylin Pharmaceuticals Inc., of San Diego, purchased an existing 150,000-square-foot building and 26 acres of land in West Chester, Ohio, as part of its previously announced facility expansion plan for commercial manufacturing of a long-acting release formulation of exenatide in Type II diabetes

A response letter was accepted by the FDA in October, and Discovery expects a decision in April. (See BioWorld Today, Feb. 15, 2005.) Through the asset purchase agreement, Discovery will pay $16 million at closing, expected in the next few days, in exchange for an assignment of an existing lease on the 21,000-square-foot facility

The potential buyout includes Abgenix's 100,000-square-foot manufacturing plant and its fully human monoclonal antibody technology, XenoMouse

Half of those employees will leave the company early in January, and the rest would be affected through the sale of the generics and dental operations (NEW sentence)and a 60,000-square-foot manufacturing plant in Fort Collins, Colo

Genzyme will pay Cell Genesys $3.2 million in cash for the assets contained in the 47,000-square-foot leased facilities

Altana AG, of Bad Homburg, Germany, withdrew its European marketing authorization application for Daxas (roflumilast) after consulting with the European Medicines Evaluation Agency. The company said a new MAA submission will be pursued after further clinical data are available. Daxas, a phosphodiesterase4 inhibitor, is an orally administered, steroid-free, anti-inflammatory agent in development to treat chronic obstructive pulmonary disease and asthma. Alteon Inc., of Parsippany, N.J., said

The 80,000-square-foot facility will be devoted to manufacturing and is intended to give Favrille the capacity to produce FavId to meet commercial needs while continuing to support additional clinical trials...In addition, the company committed to lease an adjacent 48,000-square-foot facility to house its corporate headquarters and research and warehousing operations